XML 19 R9.htm IDEA: XBRL DOCUMENT

Net Financial Result

6 Months Ended

Jun. 30, 2023

The net financial result comprises the following items for the three- and six-months ended June 30, 2023 and 2022, respectively:

	For the three months ended June 30,						For the six months ended June 30
	2023 (unaudited)			2022 (unaudited)			2023 (unaudited)			2022 (unaudited)
	(in €)
Financial income
Interest income		1,087,011			82,401			1,543,047			110,362
Financial expenses
Interest expenses		(363	)		(2,243	)		(782	)		(22,102	)
Interest on lease liabilities		(4,689	)		(5,702	)		(9,798	)		(10,429	)
Total		1,081,959			74,456			1,532,467			77,831

Interest income is derived from marketable securities and short-term deposits held by the Company and its subsidiary InflaRx GmbH:

	For the three months ended June 30,						For the six months ended June 30
	2023 (unaudited)			2022 (unaudited)			2023 (unaudited)			2022 (unaudited)
	(in €)
Foreign exchange result
Foreign exchange income		2,090,994			2,947,221			2,381,519			4,057,629
Foreign exchange expense		(1,323,348	)		(1,383,641	)		(2,751,183	)		(1,766,116	)
Total		767,646			1,563,580			(369,664	)		2,291,513

Foreign exchange income and expense is mainly derived from the translation of the U.S. Dollar cash, cash equivalents and securities held by InflaRx GmbH and InflaRx N.V.

	For the three months ended June 30,						For the six months ended June 30
	2023 (unaudited)			2022 (unaudited)			2023 (unaudited)		2022 (unaudited)
	(in €)
Other financial result		(195,567	)		(86,000	)		2,241		39,000

Other financial result is attributable to the expected credit loss allowance, which is deducted from the Company’s current and non-current financial assets.